Article Information
- Received May 25, 2021
- Revision received January 18, 2022
- Accepted January 23, 2022
- First published January 28, 2022.
- Version of record published March 23, 2022.
Author Information
Author contributions
Author contributions: W.T.B., S.A., and E.R.J. designed research; W.T.B., S.A., and E.R.J. analyzed data; W.T.B., S.A., and E.R.J. edited the paper; S.A. and E.R.J. performed research; S.A. wrote the first draft of the paper.
Disclosures
- Received May 25, 2021.
- Revision received January 18, 2022.
- Accepted January 23, 2022.
This work was supported by the National Institute on Drug Abuse R01DA042779 to W.T.B., F30 DA051117 to S.A. and T32DA007281 to E.R.J.; the ARCS Foundation S.A. We thank Dr. John T. Williams and Erica Levitt for comments on the manuscript and financial support for this project (National Institute on Drug Abuse R01DA08163 to Dr. John T. Williams); Dr. Brigitte Kieffer for providing Oprm1 fl/fl mice; Dr. Christopher Ford for providing Drd1-cre mice; Dr. Tianyi Mao for providing Adora2a-cre mice; and Katherine Suchland, Dr. James Bunzow, and Dr. Joe Lebowitz for genotyping the transgenic mice.
The authors declare no competing financial interests.
- Correspondence should be addressed to William T. Birdsong at wtbird{at}umich.edu
Funding
HHS | NIH | National Institute on Drug Abuse (NIDA)
R01DA042779; F30DA051117; R01DA008160; T32DA007281Achievement Rewards for College Scientists Foundation (ARCS)
Other Version
- previous version (January 28, 2022).
- You are viewing the most recent version of this article.
Online Impact
Article usage
In this issue
